GUARD or Anastrozole is an extremely powerful anti-estrogen officially belonging to the Aromatase Inhibitor (AI) family. This is perhaps the most commonly used AI and one of the most common anti-estrogens on the market. GUARD has proven to be very effective in breast cancer treatment, even more so than traditional RECOVER (Tamoxifen Citrate), and is a favorite anti-estrogen among many anabolic steroid users.
Countless anabolic steroid users rely on GUARD for on cycle estrogenic protection. Many anabolic steroids have the ability to aromatase and lead to excess estrogen, which in turn can lead to some of the most commonly associated side effects of anabolic steroid use.
The functions and traits of GUARD although powerful are extremely simple. As an AI GUARD functions by blocking the aromatase enzyme, which is in turn responsible for the production of estrogen. By inhibiting the aromatase process, GUARD will lower the body’s serum estrogen levels; in fact, a total suppression of estrogen by 80% has been well noted with this AI. This will prove very beneficial to numerous breast cancer patients and extremely valuable to many anabolic steroid users.
GUARD (ADEX)
Dosage
ALL REFERENCES OF USE ARE FOR RESEARCH SUBJECTS AND NOT HUMANS
Concentration: 1mg/mL
Volume: 30mL
We suggest a dosage of 0.25 mg-1 mg everyday for the duration of your anabolic steroid cycle. Each bottle is 30ml and will last for around 30 days at max dose.
Ingredients
GUARD: 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile), Food-grade USP glycol, food-grade ethyl alcohol and essential oils.
Storage
Cool and dark space like a cupboard or pantry.
Medical References
- Alder, NJ, Keihani, S, Stoddard, GJ, Myers, JB & Hotaling, JM 2018, ‘Combination therapy with clomiphene citrate and anastrozole is a safe and effective alternative for hypoandrogenic subfertile men’, BJU International, vol. 122, no. 4, pp. 688–694
- Hizan, NS, Hassan, NHM, Haron, J, Abubakar, MB, Mahdi, NMN & Gan, SH 2018, ‘Tualang honey adjunct with anastrozole improve parenchyma enhancement of breast tissue in breast cancer patients: A randomized controlled trial’, Integrative Medicine Research, vol. 7, no. 4, pp. 322–327